An Expanded Access Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer in Single, Individually-approved Patients
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Margetuximab (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Expanded access; Therapeutic Use
- Sponsors MacroGenics
- 16 Dec 2020 Status changed from recruiting to completed.
- 29 Apr 2020 Status changed from suspended to recruiting.
- 28 Jan 2019 Status changed from recruiting to suspended.